Last reviewed · How we verify
Non-Lipid Artificial Tear
A non-lipid artificial tear formulation that lubricates and protects the ocular surface by mimicking natural tear composition without lipid components.
A non-lipid artificial tear formulation that lubricates and protects the ocular surface by mimicking natural tear composition without lipid components. Used for Dry eye disease, Ocular surface lubrication and protection.
At a glance
| Generic name | Non-Lipid Artificial Tear |
|---|---|
| Sponsor | University of Seville |
| Drug class | Artificial tear / Ophthalmic lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This artificial tear product is designed to provide ocular surface lubrication and protection for dry eye disease by delivering aqueous and mucin-like components without lipid-based ingredients. Non-lipid formulations may reduce irritation in certain patient populations and provide sustained hydration of the cornea and conjunctiva. The product aims to restore tear film stability and reduce symptoms associated with dry eye syndrome.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
Common side effects
- Ocular irritation
- Transient blurred vision
- Eye discomfort
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose (NA)
- Effect of ANKASCIN 568-P Products Regulating Blood Lipid (NA)
- Artificial Tears, Tear Lipids and Tear Film Dynamics (PHASE4)
- Immediate Effects of Lipid-Based and Non-Lipid Artificial Tears on Corneal Aberrations (PHASE4)
- Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions (NA)
- Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma (PHASE2)
- Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-Lipid Artificial Tear CI brief — competitive landscape report
- Non-Lipid Artificial Tear updates RSS · CI watch RSS
- University of Seville portfolio CI